SCHEMBL1918152

SCHEMBL1918152

CCCc1nc2cc(Br)cc(C)c2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 3/20 0.38
KMT2A Q03164 3/20 0.38
ADORA3 P0DMS8 2/20 0.38
ADORA2A P29274 2/20 0.38
KDM4E B2RXH2 1/20 0.38
KDM4C Q9H3R0 1/20 0.36
NQO2 P16083 1/20 0.36
POLB P06746 2/20 0.35
NPY5R Q15761 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1918902 0.87 ADORA1 (0.51) ADORA1KMT2AADORA3ADORA2ANQO2
SCHEMBL13907870 0.83 KMT2A (0.40) ADORA1KMT2AADORA3ADORA2AKDM4E
SCHEMBL31459666 0.82 TDP1 (0.38) ADORA1KMT2ANQO2
SCHEMBL25110136 0.79 ADORA1 (0.37) ADORA1KMT2AADORA3ADORA2AKDM4E
SCHEMBL3712699 0.77 KMT2A (0.38) ADORA1KMT2AADORA3ADORA2AKDM4E
SCHEMBL9754821 0.77 ADORA1 (0.36) ADORA1KMT2AADORA3ADORA2AKDM4E
SCHEMBL158113 0.76 APEX1 (0.41) ADORA1KMT2AADORA3ADORA2AKDM4E
SCHEMBL16801763 0.75 NQO2 (0.42) ADORA1ADORA3ADORA2AKDM4ENQO2
SCHEMBL7386115 0.74 ADORA1 (0.53) ADORA1KMT2AADORA3ADORA2AKDM4E
SCHEMBL1918148 0.74 EGLN1 (0.40) KMT2AKDM4ENQO2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10077242-B2 Convergent approach to the total synthesis of telmisartan via a suzuki cross-coupling reaction VIRGINIA COMMONWEALTH UNIVERSITY (US) 2018-09-18 US claimed
US-20170260146-A1 A CONVERGENT APPROACH TO THE TOTAL SYNTHESIS OF TELMISARTAN VIA A SUZUKI CROSS-COUPLING REACTION VIRGINIA COMMONWEALTH UNIVERSITY 2017-09-14 US claimed
WO-2016089845-A1 A CONVERGENT APPROACH TO THE TOTAL SYNTHESIS OF TELMISARTAN VIA A SUZUKI CROSS-COUPLING REACTION VIRGINIA COMMONWEALTH UNIVERSITY (US) 2016-06-09 WO claimed
WO-2010081670-A2 PROCESS FOR THE PREPARATION OF BENZIMIDAZOLES LONZA LTD (CH) 2010-07-22 WO claimed
EP-3081213-B1 TRICYCLIC COMPOUND KYOWA KIRIN CO LTD (JP) 2020-04-01 EP disclosed
US-10077242-B2 Convergent approach to the total synthesis of telmisartan via a suzuki cross-coupling reaction VIRGINIA COMMONWEALTH UNIVERSITY (US) 2018-09-18 US disclosed
US-20170260146-A1 A CONVERGENT APPROACH TO THE TOTAL SYNTHESIS OF TELMISARTAN VIA A SUZUKI CROSS-COUPLING REACTION VIRGINIA COMMONWEALTH UNIVERSITY 2017-09-14 US disclosed
US-9475805-B2 Tricyclic compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-10-25 US disclosed
EP-3081213-A1 TRICYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2016-10-19 EP disclosed
WO-2016089845-A1 A CONVERGENT APPROACH TO THE TOTAL SYNTHESIS OF TELMISARTAN VIA A SUZUKI CROSS-COUPLING REACTION VIRGINIA COMMONWEALTH UNIVERSITY (US) 2016-06-09 WO disclosed
US-20150291587-A1 TRICYCLIC COMPOUND KYOWA KIRIN CO., LTD. (JP) 2015-10-15 US disclosed
US-20130267711-A1 TRICYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2013-10-10 US disclosed
US-8486980-B2 Tricyclic compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-07-16 US disclosed
US-20110201640-A1 TRICYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-18 US disclosed
EP-2327690-A1 TRICYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2011-06-01 EP disclosed
WO-2010081670-A2 PROCESS FOR THE PREPARATION OF BENZIMIDAZOLES LONZA LTD (CH) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10077242-B2 Convergent approach to the total synthesis of telmisartan via a suzuki cross-coupling reaction AGTR2, AGTR1, REN ADORA1 3746/4885KMT2A 1707/4885ADORA3 3257/4885
US-20150291587-A1 TRICYCLIC COMPOUND PPARA, PPARG, PPARD ADORA1 450/4885KMT2A 2018/4885ADORA3 654/4885
US-20130267711-A1 TRICYCLIC COMPOUND PPARA, PPARG, PPARD ADORA1 450/4885KMT2A 2018/4885ADORA3 654/4885
US-20110201640-A1 TRICYCLIC COMPOUND PPARG, PPARA, PPARD ADORA1 1219/4885KMT2A 1675/4885ADORA3 1519/4885
US-20170260146-A1 A CONVERGENT APPROACH TO THE TOTAL SYNTHESIS OF TELMISARTAN VIA A SUZUKI CROSS-COUPLING REACTION REN, AGTR1, AGTR2 ADORA1 3868/4885KMT2A 1832/4885ADORA3 3482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.